CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION

Authors: Cornelis van Tilburg, David T Jones, Rene Schmidt, Shivaram Avula, Antoinette Schouten- van Meeteren, Astrid Sehested, Enrico Opocher, Pablo Hernáiz Driever, Ruth Witt, David Ziegler, Samuel Blackman, Xin Zhao, Li-Pen Tsao, Michael Cox, Darren Hargrave, Olaf Witt

Published: 2022-11-14

DOI: 10.1093/neuonc/noac209.295

Source: Full article

CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION

Abstract